{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:54:45Z","timestamp":1787014485715,"version":"build-2736575974"},"reference-count":152,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2007,3,12]],"date-time":"2007-03-12T00:00:00Z","timestamp":1173657600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2007,5]]},"abstract":"<jats:title>SUMMARY<\/jats:title>\n                  <jats:p>\n                    <jats:bold>Background<\/jats:bold>\n                    Drug toxicity is the leading cause of acute liver failure in the United States. Further understanding of hepatotoxicity is becoming increasingly important as more drugs come to market.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Aims<\/jats:bold>\n                    (i) To provide an update on recent advances in our understanding of hepatotoxicity of select commonly used drug classes. (ii) To assess the safety of these medications in patients with pre\u2010existing liver disease and in the post\u2010liver transplant setting. (iii) To review relevant advances in toxicogenomics which contribute to the current understanding of hepatotoxic drugs.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods<\/jats:bold>\n                    A Medline search was performed to identify relevant literature using search terms including \u2018drug toxicity, hepatotoxicity, statins, thiazolidinediones, antibiotics, antiretroviral drugs and toxicogenomics\u2019.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results<\/jats:bold>\n                    Amoxicillin\u2010clavulanic acid is one of the most frequently implicated causes of drug\u2010induced liver injury worldwide. Statins rarely cause clinically significant liver injury, even in patients with underlying liver disease. Newer thiazolidinediones are not associated with the degree of liver toxicity observed with troglitazone. Careful monitoring for liver toxicity is warranted in patients who are taking antiretrovirals, especially patients who are co\u2010infected with hepatitis B and C. Genetic polymorphisms among enzymes involved in drug metabolism and HLA types may account for some of the differences in individual susceptibility to drug hepatotoxicity.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusions<\/jats:bold>\n                    Drug\u2010induced hepatotoxicity will remain a problem that carries both clinical and regulatory significance as long as new drugs continue to enter the market. Future results from ongoing multicentre collaborative efforts may help contribute to our current understanding of hepatotoxicity associated with drugs.\n                  <\/jats:p>","DOI":"10.1111\/j.1365-2036.2007.03307.x","type":"journal-article","created":{"date-parts":[[2010,7,23]],"date-time":"2010-07-23T07:13:01Z","timestamp":1279869181000},"page":"1135-1151","source":"Crossref","is-referenced-by-count":206,"title":["Review article: drug hepatotoxicity"],"prefix":"10.1111","volume":"25","author":[{"given":"C. Y.","family":"CHANG","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. D.","family":"SCHIANO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,3,12]]},"reference":[{"key":"e_1_2_9_2_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1746.2000.02074.x"},{"key":"e_1_2_9_3_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2002-30105"},{"key":"e_1_2_9_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.gastro.2005.05.006"},{"key":"e_1_2_9_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(93)90101-6"},{"key":"e_1_2_9_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/0168-8278(90)90124-A"},{"key":"e_1_2_9_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21095"},{"key":"e_1_2_9_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20081"},{"key":"e_1_2_9_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2006.02.012"},{"key":"e_1_2_9_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/lt.20204"},{"key":"e_1_2_9_11_2","first-page":"137","article-title":"Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States","volume":"17","author":"Ostapowicz G","year":"2002","journal-title":"Ann Intern Med"},{"key":"e_1_2_9_12_2","first-page":"354","article-title":"Drug\u2010related hepatotoxicity","volume":"16","author":"Navarro VJ","year":"2006","journal-title":"N Engl J Med"},{"key":"e_1_2_9_13_2","first-page":"349","article-title":"Drug\u2010induced hepatotoxicity","volume":"31","author":"Lee WM","year":"2003","journal-title":"N Engl J Med"},{"key":"e_1_2_9_14_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2002-30102"},{"key":"e_1_2_9_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2005.12.009"},{"key":"e_1_2_9_16_2","first-page":"89","article-title":"The liver and lovastatin","volume":"15","author":"Tolman KG","year":"2002","journal-title":"Am J Cardiol"},{"key":"e_1_2_9_17_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.288.23.2998"},{"key":"e_1_2_9_18_2","first-page":"105","article-title":"Safety and tolerability of pravastatin in long\u2010term clinical trials: prospective Pravastatin Pooling (PPP) Project","volume":"21","author":"Pfeffer MA","year":"2002","journal-title":"Circulation"},{"key":"e_1_2_9_19_2","doi-asserted-by":"crossref","first-page":"52C","DOI":"10.1016\/j.amjcard.2005.12.010","article-title":"Statin safety: a systematic review","volume":"8","author":"Law M","year":"2006","journal-title":"Am J Cardiol"},{"key":"e_1_2_9_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-200609000-00018"},{"key":"e_1_2_9_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007611-199809000-00016"},{"key":"e_1_2_9_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-200308000-00014"},{"key":"e_1_2_9_23_2","doi-asserted-by":"publisher","DOI":"10.1191\/0961203303lu313cr"},{"key":"e_1_2_9_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-200505000-00019"},{"key":"e_1_2_9_25_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.02.015"},{"key":"e_1_2_9_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21248"},{"key":"e_1_2_9_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2006.03.014"},{"key":"e_1_2_9_28_2","first-page":"62","article-title":"Hyperlipidemia after liver transplantation: natural history and treatment with the hydroxy\u2010methylglutaryl\u2010coenzyme A reductase inhibitor pravastatin","volume":"15","author":"Imagawa DK","year":"1996","journal-title":"Transplantation"},{"key":"e_1_2_9_29_2","doi-asserted-by":"publisher","DOI":"10.1053\/jlts.2001.29167"},{"key":"e_1_2_9_30_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1D388"},{"key":"e_1_2_9_31_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01307562"},{"key":"e_1_2_9_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840150518"},{"key":"e_1_2_9_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(02)00006-5"},{"key":"e_1_2_9_34_2","first-page":"3143","article-title":"Expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)","volume":"25","author":"National Cholesterol Education Program (NCEP)","year":"2002","journal-title":"Circulation"},{"key":"e_1_2_9_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2005.12.014"},{"key":"e_1_2_9_36_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20671"},{"key":"e_1_2_9_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2004.07.052"},{"key":"e_1_2_9_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2004.01.008"},{"key":"e_1_2_9_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(08)82704-7"},{"key":"e_1_2_9_40_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21232"},{"key":"e_1_2_9_41_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200262150-00002"},{"key":"e_1_2_9_42_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASN.0000018400.39687.8C"},{"key":"e_1_2_9_43_2","volume-title":"Zetia Prescribing Information","year":"2006"},{"key":"e_1_2_9_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2006.04.014"},{"key":"e_1_2_9_45_2","first-page":"90","article-title":"Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia","volume":"15","author":"Dujovne CA","year":"2002","journal-title":"Am J Cardiol"},{"key":"e_1_2_9_46_2","first-page":"90","article-title":"Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia","volume":"15","author":"Gagne C","year":"2002","journal-title":"Am J Cardiol"},{"key":"e_1_2_9_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2004.11.023"},{"key":"e_1_2_9_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2004.03.052"},{"key":"e_1_2_9_49_2","first-page":"271","article-title":"A comparison of the efficacy and toxic effects of sustained\u2010 vs immediate\u2010release niacin in hypercholesterolemic patients","volume":"2","author":"McKenney JM","year":"1994","journal-title":"JAMA"},{"key":"e_1_2_9_50_2","first-page":"2191","article-title":"Drug\u2010related hepatotoxicity","volume":"3","author":"Madariaga MG","year":"2006","journal-title":"N Engl J Med"},{"key":"e_1_2_9_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(02)01529-2"},{"key":"e_1_2_9_52_2","first-page":"135","article-title":"Hepatocellular injury in a patient receiving pioglitazone","volume":"21","author":"Maeda K","year":"2001","journal-title":"Ann Intern Med"},{"key":"e_1_2_9_53_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1E072"},{"key":"e_1_2_9_54_2","first-page":"132","article-title":"Hepatic failure in a patient taking rosiglitazone","volume":"18","author":"Forman LM","year":"2000","journal-title":"Ann Intern Med"},{"key":"e_1_2_9_55_2","first-page":"132","article-title":"Hepatocellular injury in a patient receiving rosiglitazone. A case report","volume":"18","author":"Al\u2010Salman J","year":"2000","journal-title":"Ann Intern Med"},{"key":"e_1_2_9_56_2","first-page":"133","article-title":"Rosiglitazone toxicity","volume":"17","author":"Ravinuthala RS","year":"2000","journal-title":"Ann Intern Med"},{"key":"e_1_2_9_57_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2002.05516.x"},{"key":"e_1_2_9_58_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-200205000-00021"},{"key":"e_1_2_9_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(01)00926-3"},{"key":"e_1_2_9_60_2","volume-title":"Avandia (Rosiglitazone Maleate) Tablets. Prescribing Information","author":"GlaxoSmithKline Pharmaceuticals","year":"2006"},{"key":"e_1_2_9_61_2","volume-title":"Actos (Pioglitazone) Prescribing Information","year":"2006"},{"key":"e_1_2_9_62_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.24.1.168"},{"key":"e_1_2_9_63_2","first-page":"S61","article-title":"Therapy of NAFLD: insulin sensitizing agents","volume":"3","author":"Caldwell SH","year":"2006","journal-title":"J Clin Gastroenterol"},{"key":"e_1_2_9_64_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2001.03553.x"},{"key":"e_1_2_9_65_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840380427"},{"key":"e_1_2_9_66_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1542-3565(04)00457-4"},{"key":"e_1_2_9_67_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20012"},{"key":"e_1_2_9_68_2","first-page":"355","article-title":"A placebo\u2010controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis","volume":"30","author":"Belfort R","year":"2006","journal-title":"N Engl J Med"},{"key":"e_1_2_9_69_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2005.41690.x"},{"key":"e_1_2_9_70_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.25.5.815"},{"key":"e_1_2_9_71_2","first-page":"80","article-title":"Rosiglitazone therapy of posttransplant diabetes mellitus","volume":"27","author":"Villanueva G","year":"2005","journal-title":"Transplantation"},{"key":"e_1_2_9_72_2","first-page":"140","article-title":"Metformin hepatotoxicity","volume":"2","author":"Deutsch M","year":"2004","journal-title":"Ann Intern Med"},{"key":"e_1_2_9_73_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2001.03972.x"},{"key":"e_1_2_9_74_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(98)00088-6"},{"key":"e_1_2_9_75_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.21.10.1659"},{"key":"e_1_2_9_76_2","first-page":"338","article-title":"Lactic acidosis in patients with diabetes treated with metformin","volume":"22","author":"Misbin RI","year":"1998","journal-title":"N Engl J Med"},{"key":"e_1_2_9_77_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2005.11.027"},{"key":"e_1_2_9_78_2","first-page":"36","article-title":"Hepatotoxicity of antiretroviral therapy","volume":"5","author":"Kontorinis N","year":"2003","journal-title":"AIDS Rev"},{"key":"e_1_2_9_79_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2004.11.017"},{"key":"e_1_2_9_80_2","first-page":"32","article-title":"Severe hepatotoxicity during combination antiretroviral treatment: incidence, liver histology, and outcome","volume":"1","author":"Puoti M","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"e_1_2_9_81_2","volume-title":"Table of grading severity of adult adverse experiences","author":"AIDS Clinical Trials Group","year":"1996"},{"key":"e_1_2_9_82_2","first-page":"186","article-title":"Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy","volume":"1","author":"Wit FW","year":"2002","journal-title":"J Infect Dis"},{"key":"e_1_2_9_83_2","first-page":"333","article-title":"A short\u2010term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV\u20101 protease. European\u2010Australian Collaborative Ritonavir Study Group","volume":"7","author":"Danner SA","year":"1995","journal-title":"N Engl J Med"},{"key":"e_1_2_9_84_2","first-page":"333","article-title":"A preliminary study of ritonavir, an inhibitor of HIV\u20101 protease, to treat HIV\u20101 infection","volume":"7","author":"Markowitz M","year":"1995","journal-title":"N Engl J Med"},{"key":"e_1_2_9_85_2","first-page":"351","article-title":"Randomised placebo\u2010controlled trial of ritonavir in advanced HIV\u20101 disease. The Advanced HIV Disease Ritonavir Study Group","volume":"21","author":"Cameron DW","year":"1998","journal-title":"Lancet"},{"key":"e_1_2_9_86_2","first-page":"34","article-title":"Hepatotoxicity associated with antiretroviral therapy containing dual vs. single protease inhibitors in individuals coinfected with hepatitis C virus and human immunodeficiency virus","volume":"1","author":"Cooper CL","year":"2002","journal-title":"Clin Infect Dis"},{"key":"e_1_2_9_87_2","unstructured":"Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolesents \u2013 A Working Group of the Office of AIDS Research Advisory Council (OARAC). Available at:http:\/\/www.aidsinfo.nih.gov\/contentfiles\/AdultandAdolescentGL.pdf(last accessed 22 March2007)."},{"key":"e_1_2_9_88_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1G598"},{"key":"e_1_2_9_89_2","first-page":"98","article-title":"Mechanism of indinavir\u2010induced hyperbilirubinemia","volume":"23","author":"Zucker SD","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"e_1_2_9_90_2","first-page":"192","article-title":"Gilbert syndrome and the development of antiretroviral therapy\u2010associated hyperbilirubinemia","volume":"15","author":"Rotger M","year":"2005","journal-title":"J Infect Dis"},{"key":"e_1_2_9_91_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.fpc.0000197465.14340.d4"},{"key":"e_1_2_9_92_2","first-page":"29","article-title":"LIVERHAART Group. Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV: the role of hepatitis B and C virus infection","volume":"1","author":"Aceti A","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"key":"e_1_2_9_93_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(03)00654-6"},{"key":"e_1_2_9_94_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(99)80020-8"},{"key":"e_1_2_9_95_2","doi-asserted-by":"publisher","DOI":"10.1086\/313594"},{"key":"e_1_2_9_96_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(00)90004-3"},{"key":"e_1_2_9_97_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2005.11.025"},{"key":"e_1_2_9_98_2","first-page":"35","article-title":"Hepatotoxicity associated with nevirapine use","volume":"15","author":"Baylor MS","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"e_1_2_9_99_2","first-page":"15","article-title":"Hepatotoxicity in HIV\u20101\u2010infected patients receiving nevirapine\u2010containing antiretroviral therapy","volume":"6","author":"Martinez E","year":"2001","journal-title":"AIDS"},{"key":"e_1_2_9_100_2","first-page":"35","article-title":"A cohort study of nevirapine tolerance in clinical practice: French Aquitaine Cohort, 1997\u20101999","volume":"15","author":"Bonnet F","year":"2002","journal-title":"Clin Infect Dis"},{"key":"e_1_2_9_101_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2002.30319"},{"key":"e_1_2_9_102_2","first-page":"363","article-title":"Comparison of first\u2010line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open\u2010label trial, the 2NN Study","volume":"17","author":"Van Leth F","year":"2004","journal-title":"Lancet"},{"key":"e_1_2_9_103_2","doi-asserted-by":"publisher","DOI":"10.1310\/N4VT-3E9U-4BKN-CRPW"},{"key":"e_1_2_9_104_2","first-page":"29","article-title":"Lack of hepatotoxicity associated with nonnucleoside reverse transcriptase inhibitors","volume":"1","author":"Palmon R","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"key":"e_1_2_9_105_2","doi-asserted-by":"publisher","DOI":"10.1086\/314026"},{"key":"e_1_2_9_106_2","first-page":"283","article-title":"Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection","volume":"5","author":"Sulkowski MS","year":"2000","journal-title":"JAMA"},{"key":"e_1_2_9_107_2","first-page":"27","article-title":"Risk factors for hepatotoxicity in patients treated with highly active antiretroviral therapy","volume":"1","author":"Bonfanti P","year":"2001","journal-title":"J Acquir Immune Defic Syndr"},{"key":"e_1_2_9_108_2","first-page":"14","article-title":"Hepatitis B and C virus co\u2010infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV\u20101 infection","volume":"22","author":"Den Brinker M","year":"2000","journal-title":"AIDS"},{"key":"e_1_2_9_109_2","first-page":"32","article-title":"Increasing mortality due to end\u2010stage liver disease in patients with human immunodeficiency virus infection","volume":"1","author":"Bica I","year":"2001","journal-title":"Clin Infect Dis"},{"key":"e_1_2_9_110_2","doi-asserted-by":"publisher","DOI":"10.1053\/jlts.2002.34921"},{"key":"e_1_2_9_111_2","doi-asserted-by":"publisher","DOI":"10.1002\/lt.20318"},{"key":"e_1_2_9_112_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1D076"},{"key":"e_1_2_9_113_2","doi-asserted-by":"publisher","DOI":"10.1053\/jlts.2002.34880"},{"key":"e_1_2_9_114_2","first-page":"64","article-title":"The burden of acute nonfulminant drug\u2010induced hepatitis in a United States tertiary referral center [corrected]","volume":"39","author":"Galan MV","year":"2005","journal-title":"J Clin Gastroenterol"},{"key":"e_1_2_9_115_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2002.34857"},{"key":"e_1_2_9_116_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.44.5.731"},{"key":"e_1_2_9_117_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.33.3.368"},{"key":"e_1_2_9_118_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(89)91633-8"},{"key":"e_1_2_9_119_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.33.3.368"},{"key":"e_1_2_9_120_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(99)70404-X"},{"key":"e_1_2_9_121_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21324"},{"key":"e_1_2_9_122_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1026610015899"},{"key":"e_1_2_9_123_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(99)70404-X"},{"key":"e_1_2_9_124_2","volume-title":"Telithromycin (Ketek) Product Information","year":"2006"},{"key":"e_1_2_9_125_2","first-page":"144","article-title":"Brief communication: severe hepatotoxicity of telithromycin: three case reports and literature review","volume":"21","author":"Clay KD","year":"2006","journal-title":"Ann Intern Med"},{"key":"e_1_2_9_126_2","first-page":"355","article-title":"Telithromycin and acute liver failure","volume":"23","author":"Graham DJ","year":"2006","journal-title":"N Engl J Med"},{"key":"e_1_2_9_127_2","first-page":"348","article-title":"Inheritance and drug response","volume":"6","author":"Weinshilboum R","year":"2003","journal-title":"N Engl J Med"},{"key":"e_1_2_9_128_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.25.10.1057"},{"key":"e_1_2_9_129_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00316090"},{"key":"e_1_2_9_130_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-200103000-00005"},{"key":"e_1_2_9_131_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(05)80620-8"},{"key":"e_1_2_9_132_2","first-page":"197A","article-title":"Homozygous mutation of cytochrome P\u2010450 2C19 is associated with troglitazone\u2010induced hepatitis","volume":"32","author":"Kumashiro R","year":"2000","journal-title":"Hepatology"},{"key":"e_1_2_9_133_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2003.50144"},{"key":"e_1_2_9_134_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-199406000-00003"},{"key":"e_1_2_9_135_2","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0031-6997(25)06816-4","article-title":"N\u2010Acetylation pharmacogenetics","volume":"37","author":"Weber WW","year":"1985","journal-title":"Pharmacol Rev"},{"key":"e_1_2_9_136_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-105-2-179"},{"key":"e_1_2_9_137_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1991.3"},{"key":"e_1_2_9_138_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-199508000-00011"},{"key":"e_1_2_9_139_2","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/S0026-895X(25)10602-0","article-title":"Interactions of dihydralazine with cytochromes P4501A: a possible explanation for the appearance of anti\u2010cytochrome P4501A2 autoantibodies","volume":"45","author":"Bourdi M","year":"1994","journal-title":"Mol Pharmacol"},{"key":"e_1_2_9_140_2","first-page":"2","article-title":"Genetic control of isoniazid metabolism in man","volume":"13","author":"Evans DA","year":"1960","journal-title":"Br Med J"},{"key":"e_1_2_9_141_2","first-page":"461","article-title":"Predisposing factors in hepatitis induced by isoniazid\u2010rifampin treatment of tuberculosis","volume":"118","author":"Gronhagen\u2010Riska C","year":"1978","journal-title":"Am Rev Respir Dis"},{"key":"e_1_2_9_142_2","doi-asserted-by":"publisher","DOI":"10.1016\/0041-3879(86)90003-6"},{"key":"e_1_2_9_143_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.47.5.717"},{"key":"e_1_2_9_144_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20215"},{"key":"e_1_2_9_145_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(94)80004-9"},{"key":"e_1_2_9_146_2","first-page":"43","article-title":"Pharmacogenetics of nevirapine\u2010associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration","volume":"15","author":"Haas DW","year":"2006","journal-title":"Clin Infect Dis"},{"key":"e_1_2_9_147_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-200008000-00004"},{"key":"e_1_2_9_148_2","first-page":"348","article-title":"Pharmacogenomics \u2010\u2010 drug disposition, drug targets, and side effects","volume":"6","author":"Evans WE","year":"2003","journal-title":"N Engl J Med"},{"key":"e_1_2_9_149_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(97)80492-8"},{"key":"e_1_2_9_150_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-200208000-00003"},{"key":"e_1_2_9_151_2","first-page":"22","article-title":"Incidence, risk factors and clinical course of thiopurine\u2010induced liver injury in patients with inflammatory bowel disease","volume":"1","author":"Bastida G","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"e_1_2_9_152_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2002.32102"},{"key":"e_1_2_9_153_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840080327"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2007.03307.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2036.2007.03307.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,23]],"date-time":"2025-02-23T03:33:57Z","timestamp":1740281637000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2007.03307.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3,12]]},"references-count":152,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2007,5]]}},"alternative-id":["10.1111\/j.1365-2036.2007.03307.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2007.03307.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,3,12]]}}}